High Levels of Estradiol, Progesterone During Pregnancy Associated With Increased Risk for HR-negative Breast Cancer
Embargo expired: 18-Oct-2012 3:00 PM EDT
Source Newsroom: American Association for Cancer Research (AACR)
Newswise — ANAHEIM, Calif. — Increased concentrations of the pregnancy hormones estradiol and progesterone were associated with an increased risk for hormone receptor-negative breast cancer diagnosed before age 50, according to the results of a nested case-control study presented at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held here Oct. 16-19, 2012.
Annekatrin Lukanova, M.D., Ph.D., associate professor at the German Cancer Research Center in Heidelberg, Germany, and colleagues examined the effects of hormonal exposure during early pregnancy and its possible association with risk for maternal breast cancer.
“Pregnancy influences maternal risk for breast cancer, but the association is complex and the biological mechanisms underlying the associations are unknown,” Lukanova said. “Understanding the mechanisms underlying the protective effect of childbearing on cancer risk can form the basis for primary prevention of breast cancer.”
Lukanova and colleagues used the Northern Sweden Maternity cohort to conduct a nested case-control study of 417 controls and 223 women who had donated blood samples during their first trimester of pregnancy and were later diagnosed with breast cancer. About three quarters of the breast cancer cases were hormone receptor (HR)-positive.
The researchers examined two groups of hormones: The first group included estradiol, estrone and progesterone, the concentrations of which increase substantially with pregnancy progression. The second group included testosterone and insulin growth factor-1 (IGF-1). During early pregnancy, concentrations of testosterone and IGF-1 are largely similar to prepregnancy concentrations.
“We found that circulating concentrations of IGF-1 and testosterone are directly associated with risk for HR-positive breast cancer, in line with studies in nonpregnant women,” Lukanova said.
Results indicated a heightened risk for HR-negative breast cancer diagnosed before 50 years of age with increased levels of estradiol and progesterone.
Lukanova noted that this study was small, that the hormones were measured during the first trimester of pregnancy only, and that further and larger studies will be necessary to characterize the association of pregnancy hormones with risk for hormone-defined maternal breast cancer.
# # #
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit www.AACR.org.
B75 Pregnancy hormones and maternal risk of hormone receptor-defined breast cancer. Annekatrin Lukanova(1), Egle Tolockiene(2), Helena Schock(1), Kjell Grankvist(2), Hans Ake Lakso(2), Helja Marja Surcel(3), Goran Wadell(2), Anne Zelenuich-Jacquotte(4), Paolo Toniolo(4), Eva Lundin(2). (1)German Cancer Research Center (DKFZ), Heidelberg, Germany, (2)University of Umea, Umea, Sweden, (3)National Institute for Health and Welfare, Oulu, Finland, (4)New York University School of Medicine, New York, NY.
Introduction: Hormonal exposure during pregnancy is believed to be associated with subsequent maternal risk of breast cancer, but so far limited epidemiological data are available.
Study design: A case-control study (223 cases and 417 controls) was nested within the Northern Sweden Maternity Cohort to explore the associations between pregnancy concentrations of sex steroid hormones and insulin-like growth factor I (IGF-I) with maternal risk of breast cancer by hormone receptor (HR) expression of the tumors. The study included women who had donated a blood sample during the first trimester of their first full-term pregnancy. Most cases had HR-positive disease: 171 (77%) estrogen receptor-positive (ER+), 157 (70%) progesterone receptor-positive (PR+) and 152 (68%) ER+/PR+ tumors. Estradiol, estrone, progesterone and testosterone were measured by high-performance liquid chromatography tandem mass spectrometry. Sex hormone-binding globulin (SHBG) and insulin-like growth factor I (IGF-I) were measured by immunoassays. For each hormone, the difference (residual) between the actual assay value for each subject and the estimated mean determined for the day of gestation when the sample was drawn was computed by local linear regression. Conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI).
Results: For HR-positive tumors, a significant direct association was observed with circulating concentrations of testosterone (e.g. OR for ER+ in the top versus bottom tertile of 1.8 (1.1-3.0), p<0.02) and IGF-I (e.g. OR for ER+ in the top versus bottom tertile of 2.0 (1.2-3.3), p<0.01). For HR-negative disease, risk estimates for a doubling of estrogens, progesterone and SHBG concentrations were above unity, but did not reach statistical significance with the exception of progesterone for PR-negative tumors (OR 2.0 (1.0-3.9), p<0.04). In analyses limited to ER-negative tumors diagnosed up to age 50 (n=38), these associations were stronger, but only of borderline significance. For PR-negative tumors diagnosed up to age 50 (n=49), the associations were significant for estradiol (OR 1.8 (1.0-3.1), p<0.04), progesterone (OR 2.6 (1.1-6.1), p<0.03) and SHBG (OR 1.8 (1.0-3.0), p<0.04). Adjustments for maternal height, weight, smoking, hypertension during pregnancy, child’s sex, weight and length had negligible effect on risk estimates. Associations were similar by combined ER/PR tumor status or when limited to cases diagnosed ≥10 years after blood donation.
Conclusions: In this nested case-control study hormone concentrations during early pregnancy were associated with risk of maternal breast cancer but the associations differed by hormone receptor expression of the tumors. For hormones with placental contribution to circulating concentrations (estrogens and progesterone), there were indications for positive associations with risk of maternal HR-negative breast cancer. For hormones, with similar concentrations during early pregnancy and in the non-pregnant state (testosterone and IGF-I), direct associations with HR-positive breast cancer were observed, in line with most available epidemiological data in non-pregnant women. Larger studies are necessary to characterize the association of pregnancy hormones with risk of hormone-defined maternal breast cancer.